Proyecto de la Unión Europea – Grupo Europa contra el Cáncer


Published on

Proyecto de la Unión Europea – Grupo Europa contra el Cáncer. Alfredo Carrato Mena. I Jornadas Técnicas de la Estrategia en Cáncer del SNS (Madrid, Ministerio de Sanidad y Consumo, 2007)

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Proyecto de la Unión Europea – Grupo Europa contra el Cáncer

  1. 1. I Jornada Técnica de la ESTRATEGIA EN CÁNCER DEL SISTEMA NACIONAL DE SALUD Madrid, MSC, 25 y 26 de Junio de 2007. PROYECTO DE LA UNIÓN EUROPEA: GRUPO EUROPEO CONTRA EL CÁNCER Alfredo Carrato Catedrático y Jefe de Servicio Oncología Médica Hospital Universitario de Elche, Univ. Miguel Hernández
  3. 3. Cancer Incidence Rates*, All Sites Combined, All Races, 1975-2000 Rate Per 100,000 700 600 Men 500 Both Sexes 400 Women 300 200 100 0 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 *Age-adjusted to the 2000 US standard population. Source: Surveillance, Epidemiology, and End Results Program, 1973-1999, Division of Cancer Control and Population Sciences, National Cancer Institute, 2003.
  4. 4. SITUACIÓN DEL CÁNCER EN ESPAÑA 2003 • 162.000 nuevos casos y 95.000 defunciones. • El cáncer es la primera causa de fallecimiento por delante de las enfermedades cardiovasculares. • Uno de cada 3 hombres y una de cada 5 mujeres se diagnosticarán de cáncer en algún momento de su vida. • El cáncer colorrectal es el más frecuente con 25.600 casos nuevos anuales • Los más frecuentes: – en hombres son el de pulmón (16.600 nuevos casos/año), el colorrectal (14.204) y próstata (13.212). – En mujeres el de mama (15.979), colorrectal (11.461) y útero (7.164). • Supervivencia a 5 años (57%): 64% en mujeres y 50% en hombres
  5. 5. Gene-Environment Interaction and Likelihood of Developing Cancer A cancer gene could be expressed without any environmental influence or only when activated by environmental factors. Lichtenstein P. N Engl J Med 2000; 343:78-85
  6. 6. FRENTES EN LA LUCHA CONTRA EL CÁNCER • Aumento de conocimientos sobre la biología del cáncer (Incremento de la investigación básica, traslacional y clínica) • Prevención primaria (Hábitos saludables, fármacos, cirugía, etc.) • Prevención Secundaria (Diagnóstico precoz) • Mejorando el diagnóstico (Innovación tecnológica) • Mejorando el tratamiento (Fomento de la investigación traslacional y clínica. Nuevos fármacos y estrategias. Tratamientos individualizados, administrados por profesionales bien entrenados)
  7. 7. Tobacco Use in the US, 1900-2000 5000 100 4500 90 Per Capita Cigarette Consumption Age-Adjusted Lung Cancer Death 4000 80 3500 70 Per capita cigarette consumption 3000 60 Rates* 2500 50 Male lung cancer death rate 2000 40 1500 30 1000 20 500 10 Female lung cancer death rate 0 0 1900 1905 1910 1915 1920 1925 1930 1935 1940 1945 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 Year *Age-adjusted to 2000 US standard population. Source: Death rates: US Mortality Public Use Tapes, 1960-2000, US Mortality Volumes, 1930- 1959, National Center for Health Statistics, Centers for Disease Control and Prevention, 2002. Cigarette consumption: US Department of Agriculture, 1900-2000.
  8. 8. Trends in Obesity* Prevalence (%), By Gender, Adults Aged 20 to 74, US, 1960-2000 45 40 34 35 31 30 28 Prevalence (%) 26 23 25 21 20 17 16 17 15 13 15 12 13 15 11 10 5 0 Both sexes Men Women NHES I (1960-62) NHANES I (1971-74) NHANES II (1976-80) NHANES III (1988-94) NHANES 1999-2000 *Obesity is defined as a body mass index of 30 kg/m2 or greater. Source: National Health Examination Survey 1960-1962, National Health and Nutrition Examination Survey, 1971-1974, 1976-1980, 1988-1994, 1999-2000, National Center for Health Statistics, Centers for Disease Control and Prevention, 2002.
  9. 9. Supervivencia a 5 años en cáncer en la UE
  10. 10. European Alliance Against Cancer • Justified by the challenge that cancer represents for Europe on the human, scientific and political fronts. • The Alliance had come about as a result of a proposal made by European Ministers of Health in April 2005. • Twenty-three representatives from European Member States were present at the first meeting in Paris, December 13, 2005 • There was a presentation by each country of their national organisation in the area of cancer, key challenge, innovative area of working and expectations from the Alliance. • Policies, programmes and projects implemented by the European Commission were also presented.
  11. 11. Mission Statement • quot;Cancer is a major health challenge for Europe. It is the second cause of mortality and more than two million new cases are recorded each year. • The European Alliance against Cancer aims: • To define, promote and offer joint actions through voluntary cooperation to strengthen national measures and to ensure equal access to prevention and treatment for all European citizens, and to improve outcomes including patients’ overall experience of care. • To explore ways of supporting research efforts and their implementation into practice.quot;
  12. 12. Discussion on suggested areas of collaboration • Clinical guidelines - Teresa Moss, UK • Tumour Banks* - Marcella Mottolese, Italy (E de Álava) • High throughput technologies* – François Amalric, France (X Bustelo) • Education and Training* – Miklós Kásler and Maria Godeny , Hungary (A Carrato) • Clinical trials database – Thierry Le Chevalier, France • Primary prevention -Harald Zur Hausen, Germany • Secondary prevention. Sergio Pecorelli, Italy
  13. 13. Regina Elena Cancer Institute, Rome, Steering Committee Meeting, 27 April 2006 • 11 members of the steering committee were present at the meeting, representing 10 countries. • In Europe, there are major differences in the level of health care between and within countries. • EAAC was set up as an Alliance focused on political issues in cancer and therefore one of its objectives is to set the minimum service which should be available in Europe • Patients can move in Europe to get treatment with E112 documents which allow patients to be treated in another country because the ‘best treatment” is not available in their own country.
  14. 14. Educational Working Group Meeting National Institute of Oncology, Budapest, 17th July, 2006 • Discussion about the educational systems of the present representatives (3) of the participant countries (9). Christine Lepage (EAAC member, France) – Alfredo Carrato (Spain) – Maria Gődény (Hungary) – Breborowicz (Poland) – • Minimum Recommendations have to be pointed for – Undergraduate programs (medical faculties, universities) – Graduate programs (resident’s training) – CME
  15. 15. Tumor Bank Working Group Meeting Regina Elena Cancer Institute Rome, 7th December, 2006 Distribución de tareas entre los miembros del equipo: • preparar un documento para los Ministros de Sanidad de cada nacioón acerca de las condiciones mínimas que deben tener los bancos de tumores europeos, • Una guía para la promoción de bancos nuevos, como para la acreditación de bancos ya existentes, allá donde aún no se hayan puesto en marcha sistemas de acreditación de biobancos (cualquier lugar excepto UK).
  16. 16. Budget • France would finance the work of the Alliance and host the secretariat during the first year of its activities. • It was agreed that each country should be asked to make a contribution to an initial budget for the next three years of the EAAC's activity and that individual working groups could also look for further funding from other sources such as the EC. • It was agreed that industry funding for meetings was not acceptable. • France, Germany, Italy, Portugal and Spain all thought that they would be able to secure funding. Representatives from Hungary, Ireland and Luxembourg were not able to commit without further consultation and the Teresa Moss, for the UK, was sure that she would not be able to secure funding.
  17. 17. FACTORES CRÍTICOS PARA EL ÉXITO EN EL PROGRESO DE LA ONCOLOGÍA Impulsar la colaboración entre todos los sectores y centrarla alrededor del paciente Incremento inversiones en prev formac asist e investig cáncer Gobiernos Nacionales y otros ... Unión Europea Industria Agencias Reguladoras Farmacéutica Paciente Centros de Sociedades Investigación Científicas Instituciones Instituciones Académicas Clínicas
  18. 18. ¡Gracias!